Orsini Healthcare Specialty Pharmacy announced that it has been selected by Alnylam Pharmaceuticals, Inc to distribute Onpattro (patisiran) lipid complex injection. Orsini Healthcare Specialty Pharmacy is one of two specialty pharmacies selected to provide nationwide distribution for Onpattro.
Onpattro is the first-of-its kind RNA interference (RNAi) therapeutic approved by the United States Food and Drug Administration (FDA) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Hereditary amyloidosis (hATTR amyloidosis) represents a major unmet medical need with significant morbidity and mortality. The median survival is 4.7 years following diagnosis. Onpattro is administered through intravenous (IV) infusion once every three weeks by a healthcare professional, at either an infusion clinic or in the patient's home.
"The approval of Onpattro is an important milestone for patients with hATTR amyloidosis with polyneuropathy, who have had limited treatment options," said David Frobel, Senior Vice President at Orsini Healthcare. "Orsini Healthcare is proud to be able to be part of the distribution network for ONPATTRO and to be able to support patients and their families with this devastating disease."